Trial Profile
Prevention and treatment of kidney transplantation rejection by means of innovative therapeutic apheresis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2015
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 28 Jul 2011 New trial record